Abstract 2057P
Background
Aging-related deficits that eventually manifest as frailty are emerging as an important determinant for quality of life and emotional health in older patients with cancer. Prevalence of frailty in long-term prostate cancer survivors and its impact on quality of life have not been investigated so far. The objective of the current study was (I) to assess the prevalence of frailty and (II) to elucidate the relationship between frailty, quality of life and emotional health in long-term prostate cancer survivors after radical prostatectomy.
Methods
2979 prostate cancer survivors from the multicenter German Familial Prostate Cancer Database were included. Patients completed the following standardized patient-reported outcome measures of interest: frailty (Groningen Frailty Indicator, GFI), quality of life (EORTC QL2), and emotional health (anxiety/depression symptoms, PHQ-4). Chi-square tests and Wilcoxon-Mann-Whitney tests were used to detect differences of selected variables between frail and non-frail patients. Associations were assessed using multiple linear regression analysis.
Results
The patients’ mean age was 79.4 years (SD = 6.4) and mean time since radical prostatectomy was 17.4 years (SD = 3.8). 33.1% (985/2979) of patients were classified as frail (GFI ≥4). Regarding mental health and quality of life, frail patients reported more often symptoms of depression (24.0% vs. 4.0%; p<0.001) and anxiety (20.6% vs. 2.0%; p<0.001) as well as lower quality of life (M = 53.4 (SD = 19.2) vs. M = 72.7 (SD = 16.0); p<0.001) compared to non-frail patients. Frailty was significantly associated with depression (OR 1.68; CI 1.49-1.89), anxiety (OR 1.75; CI 1.55-1.97), lower quality of life (OR 0.72; CI 0.67-0.77), higher age (OR 1.04; CI 1.03-1.07), and a missing partnership (OR 1.83; CI 1.37-2.45).
Conclusions
Every third long-term prostate cancer survivor after radical prostatectomy was frail. The associations with lower quality of life and poorer mental health indicates the need for an integrated care approach including further geriatric assessment and possible interventions to improve health outcomes of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06